WEBSITE BSE:540975 NSE: ASTERDM Inc. Year: 2008 Industry: Hospital & Healthcare Services My Bucket: Add Stock
Last updated: 15:59
No Notes Added Yet
1. Business Overview
Aster DM Healthcare Ltd. is a leading integrated healthcare service provider. Historically, it operated a large network of hospitals, clinics, and retail pharmacies across India and the Gulf Cooperation Council (GCC) countries. The company offers a comprehensive range of healthcare services, from primary care to tertiary and quaternary care, across various specialties. Its core business model involves generating revenue through patient fees for medical treatments, diagnostic services, consultations, and sales from its retail pharmacies. Recently, the company announced a strategic separation of its GCC business, with Aster DM Healthcare Ltd. (the listed Indian entity) focusing solely on its rapidly expanding operations within India post-demerger.
2. Key Segments / Revenue Mix
Post the divestment of its GCC operations, Aster DM Healthcare Ltd.'s revenue mix will be entirely India-focused and predominantly derived from:
Hospitals: Operating multi-specialty tertiary and quaternary care hospitals across several states, providing complex medical and surgical services. This is expected to be the primary revenue driver.
Clinics & Diagnostic Centres: Providing outpatient services, primary care, and a range of diagnostic imaging and laboratory services, often acting as feeder networks to its hospitals.
Retail Pharmacies: Operating standalone pharmacies and in-hospital pharmacies, complementing its care delivery.
The geographical focus will be entirely on the Indian market, particularly strong in southern states like Kerala and Karnataka, with ongoing expansion into other regions.
3. Industry & Positioning
The Indian healthcare industry is large, growing rapidly, and highly fragmented, with a significant role played by the private sector in specialized and advanced medical care. Aster DM Healthcare Ltd. positions itself as a premium, multi-specialty healthcare provider, offering a comprehensive range of services. It competes with other major hospital chains such as Apollo Hospitals, Fortis Healthcare, Max Healthcare Institute, and Manipal Hospitals. The company holds a strong regional presence in South India, known for its clinical expertise and established brand reputation, aiming to expand its footprint across the country.
4. Competitive Advantage (Moat)
Brand Reputation & Clinical Excellence: Strong brand recognition and trust built over years, especially in its core markets, stemming from a reputation for quality medical care, advanced infrastructure, and experienced medical professionals.
Integrated Healthcare Delivery: Offering a continuum of care through a network of hospitals, clinics, and pharmacies allows for comprehensive patient management, enhancing loyalty and cross-referrals.
Doctor Relationships: Ability to attract, retain, and collaborate with leading medical talent due to its modern facilities, diverse case mix, and professional environment.
Scale & Network (India Focus): A growing network of hospitals and associated facilities within India provides economies of scale in procurement, shared services, and a broader reach for patient acquisition.
5. Growth Drivers
Rising Healthcare Expenditure in India: Increasing disposable incomes, growing health awareness, and expanding health insurance penetration are fueling demand for quality healthcare services.
Demographic Shifts: An aging population and a rising prevalence of non-communicable and chronic diseases necessitate greater demand for specialized medical care.
Infrastructure Deficit: India has a significant undersupply of quality healthcare infrastructure, presenting opportunities for expansion and new facility development.
Strategic Expansion: Focused expansion through greenfield and brownfield projects in existing and new geographies within India, including Tier 2/3 cities.
Medical Value Travel: India's potential to attract international patients seeking high-quality, cost-effective medical treatments, though this is a smaller component of overall growth.
6. Risks
Regulatory and Policy Changes: The healthcare sector is highly regulated. Changes in pricing controls, land acquisition policies, medical ethics regulations, or quality standards could impact profitability and operations.
Talent Attrition & Shortage: A persistent shortage of skilled doctors, nurses, and paramedical staff, coupled with high attrition rates, can lead to increased costs and operational challenges.
Intense Competition: High competition from both established large hospital chains and new entrants can lead to pricing pressures and margin erosion.
Execution Risk: Challenges associated with the successful execution of new projects, including cost overruns, delays in commissioning, and achieving desired occupancy and profitability levels.
Economic Downturn: An economic slowdown could lead to reduced discretionary healthcare spending and impact the growth of health insurance.
Operational Contingencies: Risks associated with unforeseen medical emergencies, equipment failures, or cybersecurity breaches.
7. Management & Ownership
Aster DM Healthcare was founded by Dr. Azad Moopen, who continues to lead the company as Chairman and Managing Director. The promoter group, led by Dr. Moopen, holds a significant ownership stake, indicating strong long-term commitment and alignment with shareholder interests. The management team is generally well-regarded for its clinical and operational expertise, with a proven track record of scaling a large, multi-geography healthcare enterprise. The recent strategic decision to demerge the GCC business reflects a focused strategy for the Indian operations, which will be managed by a dedicated leadership team.
8. Outlook (Balanced View)
Aster DM Healthcare Ltd., as a pure-play India-focused entity post the GCC divestment, is well-positioned to capitalize on the robust growth opportunities within the Indian healthcare market. The strategic simplification of its business model allows for dedicated capital allocation, management focus, and a clearer investment narrative. Its established brand, integrated care model, and strong presence in key South Indian markets provide a solid foundation for future expansion. However, the company faces significant challenges including intense competition, the complex regulatory environment, and the substantial execution risks inherent in scaling up healthcare infrastructure. The ability of the management team to efficiently deploy capital into profitable expansion projects, attract and retain top medical talent, and navigate competitive pressures will be critical in determining its long-term success and value creation in a dynamic and capital-intensive sector.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹39131 Cr.
Stock P/E 116.2
P/B 8.6
Current Price ₹755.3
Book Value ₹ 88.3
Face Value 10
52W High ₹770
Dividend Yield 0%
52W Low ₹ 519.8
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 955 | 974 | 1002 | 1086 | 1050 | 1000 | 1078 | 1197 | 1186 | 1182 |
| Other Income | 9 | 4 | 49 | 35 | 33 | 31 | 33 | 28 | 28 | 36 |
| Total Income | 964 | 978 | 1051 | 1122 | 1083 | 1032 | 1111 | 1225 | 1214 | 1219 |
| Total Expenditure | 803 | 814 | 838 | 867 | 861 | 808 | 871 | 947 | 975 | 950 |
| Operating Profit | 161 | 163 | 212 | 255 | 222 | 223 | 241 | 278 | 239 | 269 |
| Interest | 25 | 30 | 29 | 31 | 31 | 32 | 31 | 31 | 31 | 30 |
| Depreciation | 57 | 58 | 60 | 62 | 62 | 64 | 63 | 66 | 68 | 67 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | -24 | -26 | -4 | -0 | -28 | 0 |
| Profit Before Tax | 79 | 75 | 123 | 161 | 105 | 101 | 142 | 181 | 112 | 172 |
| Provision for Tax | 11 | 31 | 39 | 53 | 37 | 5 | 43 | 46 | 44 | 10 |
| Profit After Tax | 68 | 45 | 84 | 108 | 68 | 96 | 99 | 135 | 67 | 162 |
| Adjustments | 111 | -69 | 5061 | -12 | -11 | -17 | -14 | -25 | -15 | -22 |
| Profit After Adjustments | 179 | -24 | 5145 | 97 | 57 | 79 | 86 | 110 | 52 | 140 |
| Adjusted Earnings Per Share | 3.6 | -0.5 | 103 | 1.9 | 1.1 | 1.6 | 1.7 | 2.1 | 1 | 2.7 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 3876 | 5250 | 5931 | 6721 | 7963 | 8652 | 8608 | 10253 | 2994 | 3699 | 4138 | 4643 |
| Other Income | 23 | 25 | 37 | 45 | 35 | 38 | 50 | 51 | 37 | 25 | 148 | 125 |
| Total Income | 3899 | 5275 | 5968 | 6767 | 7997 | 8690 | 8658 | 10304 | 3031 | 3724 | 4287 | 4769 |
| Total Expenditure | 3358 | 4789 | 5582 | 6089 | 7074 | 7363 | 7506 | 8720 | 2536 | 3112 | 3365 | 3743 |
| Operating Profit | 541 | 486 | 386 | 678 | 924 | 1327 | 1153 | 1584 | 495 | 612 | 922 | 1027 |
| Interest | 91 | 205 | 371 | 204 | 205 | 391 | 334 | 307 | 96 | 119 | 133 | 123 |
| Depreciation | 144 | 243 | 322 | 298 | 306 | 586 | 618 | 641 | 192 | 220 | 249 | 264 |
| Exceptional Income / Expenses | 0 | 0 | 416 | 130 | -2 | -20 | 0 | 0 | 0 | 0 | -50 | -32 |
| Profit Before Tax | 306 | 38 | 108 | 308 | 410 | 330 | 205 | 637 | 195 | 261 | 471 | 607 |
| Provision for Tax | 34 | 29 | 11 | 26 | 43 | 15 | 27 | 36 | 36 | 57 | 134 | 143 |
| Profit After Tax | 272 | 8 | 98 | 282 | 367 | 315 | 178 | 601 | 160 | 205 | 337 | 463 |
| Adjustments | -139 | -67 | 4 | -13 | -34 | -38 | -30 | -75 | 265 | -75 | 5041 | -76 |
| Profit After Adjustments | 133 | -59 | 102 | 269 | 333 | 277 | 148 | 526 | 425 | 129 | 5378 | 388 |
| Adjusted Earnings Per Share | 3.4 | -1.5 | 2.5 | 5.3 | 6.6 | 5.6 | 3 | 10.5 | 8.5 | 2.6 | 107.7 | 7.5 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 12% | -26% | -14% | 1% |
| Operating Profit CAGR | 51% | -17% | -7% | 5% |
| PAT CAGR | 64% | -18% | 1% | 2% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 29% | 43% | 37% | NA% |
| ROE Average | 9% | 6% | 8% | 9% |
| ROCE Average | 11% | 7% | 9% | 10% |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 1484 | 420 | 1875 | 2832 | 3214 | 3272 | 3372 | 3953 | 4448 | 4560 | 3428 |
| Minority's Interest | 762 | 177 | 375 | 358 | 466 | 446 | 462 | 529 | 412 | 470 | 223 |
| Borrowings | 612 | 2577 | 1891 | 1578 | 1966 | 1892 | 1755 | 1466 | 1312 | 446 | 484 |
| Other Non-Current Liabilities | 312 | 602 | 462 | 488 | 615 | 3072 | 2835 | 3014 | 4008 | 1218 | 1586 |
| Total Current Liabilities | 1239 | 1967 | 2201 | 2224 | 2668 | 3722 | 3196 | 3559 | 4655 | 5831 | 879 |
| Total Liabilities | 4409 | 5743 | 6804 | 7479 | 8928 | 12405 | 11620 | 12521 | 14836 | 17983 | 6600 |
| Fixed Assets | 2237 | 2507 | 3520 | 3738 | 4289 | 7124 | 6749 | 7009 | 9052 | 3175 | 3920 |
| Other Non-Current Assets | 372 | 730 | 812 | 872 | 1023 | 1186 | 1242 | 1416 | 862 | 642 | 779 |
| Total Current Assets | 1801 | 2506 | 2472 | 2869 | 3617 | 4096 | 3629 | 4096 | 4922 | 7312 | 1901 |
| Total Assets | 4409 | 5743 | 6804 | 7479 | 8928 | 12405 | 11620 | 12521 | 14836 | 17983 | 6600 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 248 | 248 | 253 | 131 | 192 | 225 | 115 | 235 | 299 | 365 | 82 |
| Cash Flow from Operating Activities | 236 | 203 | 361 | 537 | 601 | 1223 | 1569 | 1314 | 1834 | 158 | 425 |
| Cash Flow from Investing Activities | -448 | -786 | -1153 | -523 | -709 | -667 | -330 | -570 | -972 | -885 | 6015 |
| Cash Flow from Financing Activities | 203 | 578 | 654 | 46 | 134 | -675 | -1116 | -686 | -817 | 1053 | -6358 |
| Net Cash Inflow / Outflow | -10 | -5 | -138 | 61 | 26 | -119 | 123 | 58 | 45 | 326 | 82 |
| Closing Cash & Cash Equivalent | 248 | 253 | 131 | 192 | 225 | 115 | 235 | 299 | 365 | 697 | 165 |
| # | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 3.41 | -1.46 | 2.52 | 5.32 | 6.59 | 5.57 | 2.97 | 10.53 | 8.51 | 2.59 | 107.66 |
| CEPS(Rs) | 10.71 | 6.23 | 10.42 | 11.47 | 13.34 | 18.13 | 16 | 24.86 | 7.04 | 8.5 | 11.72 |
| DPS(Rs) | 0 | 0.04 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 123 |
| Book NAV/Share(Rs) | 38.19 | 10.41 | 46.51 | 56.06 | 63.61 | 65.86 | 67.85 | 79.14 | 81.42 | 83.63 | 60.96 |
| Core EBITDA Margin(%) | 13.36 | 8.79 | 5.89 | 9.41 | 11.16 | 14.9 | 12.81 | 14.95 | 15.29 | 15.86 | 18.69 |
| EBIT Margin(%) | 10.25 | 4.62 | 8.08 | 7.62 | 7.73 | 8.33 | 6.26 | 9.2 | 9.73 | 10.28 | 14.59 |
| Pre Tax Margin(%) | 7.9 | 0.72 | 1.83 | 4.58 | 5.15 | 3.81 | 2.38 | 6.21 | 6.53 | 7.06 | 11.38 |
| PAT Margin (%) | 7.02 | 0.16 | 1.64 | 4.19 | 4.61 | 3.64 | 2.07 | 5.86 | 5.33 | 5.53 | 8.14 |
| Cash Profit Margin (%) | 10.73 | 4.79 | 7.08 | 8.62 | 8.46 | 10.41 | 9.24 | 12.11 | 11.74 | 11.48 | 14.15 |
| ROA(%) | 6.17 | 0.16 | 1.55 | 3.94 | 4.48 | 2.95 | 1.48 | 4.98 | 1.17 | 1.25 | 2.74 |
| ROE(%) | 18.33 | 0.86 | 8.5 | 11.97 | 12.15 | 9.7 | 5.35 | 16.41 | 3.98 | 4.97 | 9.32 |
| ROCE(%) | 15.42 | 7.69 | 11.45 | 10.43 | 11 | 11.77 | 9.03 | 15.96 | 4.52 | 5.76 | 11.46 |
| Receivable days | 83.28 | 77.4 | 80.92 | 76.95 | 81.94 | 92.71 | 92.97 | 71.9 | 265.57 | 235.68 | 118.99 |
| Inventory Days | 29.27 | 25.08 | 28.81 | 31.3 | 31.15 | 35.71 | 38.37 | 33.37 | 142.1 | 144.94 | 76.04 |
| Payable days | 129.14 | 126.99 | 143.07 | 144.32 | 140.26 | 224.56 | 296.26 | 261.62 | 1195.85 | 1279.99 | 751.14 |
| PER(x) | 0 | 0 | 0 | 31.42 | 23.44 | 17.14 | 46.19 | 18.69 | 28.39 | 158.09 | 4.5 |
| Price/Book(x) | 0 | 0 | 0 | 2.98 | 2.43 | 1.45 | 2.02 | 2.49 | 2.97 | 4.89 | 7.95 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.49 | 25.37 |
| EV/Net Sales(x) | 0.3 | 0.66 | 0.51 | 1.56 | 1.29 | 0.87 | 1.03 | 1.14 | 4.78 | 5.45 | 5.76 |
| EV/Core EBITDA(x) | 2.17 | 7.11 | 7.79 | 15.49 | 11.1 | 5.68 | 7.68 | 7.35 | 28.9 | 32.98 | 25.88 |
| Net Sales Growth(%) | 0 | 35.45 | 12.98 | 13.32 | 18.47 | 8.65 | -0.5 | 19.11 | -70.8 | 23.54 | 11.88 |
| EBIT Growth(%) | 0 | -38.88 | 97.47 | 6.81 | 20.2 | 17.15 | -25.28 | 76.35 | -69.12 | 30.48 | 58.76 |
| PAT Growth(%) | 0 | -96.98 | 1087.82 | 188.82 | 30.4 | -14.33 | -43.49 | 244.82 | -73.45 | 28.25 | 64.5 |
| EPS Growth(%) | 0 | -142.88 | 272.36 | 110.88 | 23.89 | -15.55 | -46.61 | 254.26 | -19.22 | -69.57 | 4059.81 |
| Debt/Equity(x) | 0.73 | 7.91 | 1.47 | 0.83 | 0.87 | 0.91 | 0.68 | 0.55 | 0.52 | 0.42 | 0.19 |
| Current Ratio(x) | 1.45 | 1.27 | 1.12 | 1.29 | 1.36 | 1.1 | 1.14 | 1.15 | 1.06 | 1.25 | 2.16 |
| Quick Ratio(x) | 1.2 | 1.07 | 0.89 | 1.01 | 1.08 | 0.85 | 0.88 | 0.87 | 0.78 | 0.97 | 2.06 |
| Interest Cover(x) | 4.37 | 1.18 | 1.29 | 2.51 | 3 | 1.84 | 1.61 | 3.08 | 3.04 | 3.19 | 4.55 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0.28 | 0.36 | 0.62 | 0.34 | 0.22 | 0.19 | 0.09 | 0.03 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 41.88 | 41.88 | 41.88 | 41.88 | 41.88 | 41.89 | 40.39 | 40.39 | 40.39 | 40.39 |
| FII | 41 | 33.48 | 27.08 | 23.85 | 22.62 | 21.66 | 19.64 | 18.72 | 18.46 | 17.18 |
| DII | 7.15 | 13.7 | 16.35 | 20.91 | 22.91 | 24.58 | 25.28 | 26.32 | 26.12 | 27.58 |
| Public | 9.97 | 10.94 | 14.69 | 13.36 | 12.59 | 11.86 | 14.69 | 14.56 | 15.02 | 14.85 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 20.92 | 20.92 | 20.92 | 20.92 | 20.92 | 20.92 | 20.92 | 20.93 | 20.93 | 20.93 |
| FII | 20.48 | 16.72 | 13.52 | 11.91 | 11.3 | 10.82 | 10.17 | 9.7 | 9.57 | 8.9 |
| DII | 3.57 | 6.84 | 8.17 | 10.44 | 11.44 | 12.28 | 13.1 | 13.64 | 13.53 | 14.29 |
| Public | 4.98 | 5.46 | 7.34 | 6.67 | 6.29 | 5.93 | 7.61 | 7.54 | 7.78 | 7.69 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 49.95 | 49.95 | 49.95 | 49.95 | 49.95 | 49.95 | 51.81 | 51.81 | 51.81 | 51.81 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.